Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1983 1
1984 1
1986 1
1987 1
1989 2
1991 1
1992 1
1995 2
1996 1
1997 1
2002 1
2003 1
2004 1
2005 2
2006 1
2007 3
2008 1
2011 2
2012 1
2013 2
2015 3
2016 3
2017 1
2018 1
2019 2
2021 4
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG; PRECISION investigators. Schlaich MP, et al. Lancet. 2022 Dec 3;400(10367):1927-1937. doi: 10.1016/S0140-6736(22)02034-7. Epub 2022 Nov 7. Lancet. 2022. PMID: 36356632 Clinical Trial.
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Heerspink HJL, et al. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Lancet. 2019. PMID: 30995972 Clinical Trial.
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Verma S, et al. Circulation. 2021 Dec 7;144(23):1845-1855. doi: 10.1161/CIRCULATIONAHA.121.056290. Epub 2021 Oct 28. Circulation. 2021. PMID: 34710343 Free article. Clinical Trial.
Renal hemodynamics in patients with resistant hypertension and type 2 diabetes mellitus.
Manukyan MA, Falkovskaya AY, Zyubanova IV, Solonskaya EI, Lichikaki VA, Ryabova TR, Vtorushina AA, Khunkhinova SA, Skomkina IA, Yevtukh AA, Gusakova AM, Mordovin VF. Manukyan MA, et al. Among authors: mordovin vf. Kardiologiia. 2023 Aug 31;63(8):42-49. doi: 10.18087/cardio.2023.8.n2468. Kardiologiia. 2023. PMID: 37691504 English, Russian.
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.
Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators. Cohen AT, et al. N Engl J Med. 2016 Aug 11;375(6):534-44. doi: 10.1056/NEJMoa1601747. Epub 2016 May 27. N Engl J Med. 2016. PMID: 27232649 Free article. Clinical Trial.
Durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial.
Pekarskiy S, Baev A, Falkovskaya A, Lichikaki V, Sitkova E, Zubanova I, Manukyan M, Tarasov M, Mordovin V, Popov S. Pekarskiy S, et al. Among authors: mordovin v. Heliyon. 2022 Jan 13;8(1):e08747. doi: 10.1016/j.heliyon.2022.e08747. eCollection 2022 Jan. Heliyon. 2022. PMID: 35146146 Free PMC article.
Favorable effect of renal denervation on elevated renal vascular resistance in patients with resistant hypertension and type 2 diabetes mellitus.
Manukyan M, Falkovskaya A, Mordovin V, Pekarskiy S, Zyubanova I, Solonskaya E, Ryabova T, Khunkhinova S, Vtorushina A, Popov S. Manukyan M, et al. Among authors: mordovin v. Front Cardiovasc Med. 2022 Dec 14;9:1010546. doi: 10.3389/fcvm.2022.1010546. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36601066 Free PMC article.
48 results